Russia to compensate drugmakers for price freeze

21 May 2016

The Russian national Parliament (State Duma) has put forward an initiative to provide financial support to domestic and multinational pharmaceutical producers (operating their plants in Russia), that will freeze the prices for their drugs for the period up to three years.

This has already been confirmed by Andrei Isayev, Deputy Head of the Russian State Duma, according to which all the producers, which are interested in this proposal, should sign an agreement with the Russian government, reports The Pharma Letter’s local correspondent.

It is planned that the mechanism of the provision of such support will be designed by the Russian government in the coming months, along with the planned amount of compensation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK